{
    "clinical_study": {
        "@rank": "89051", 
        "arm_group": [
            {
                "arm_group_label": "candesartan", 
                "arm_group_type": "Experimental", 
                "description": "Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd"
            }, 
            {
                "arm_group_label": "amlodipine", 
                "arm_group_type": "Experimental", 
                "description": "Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical trial to evaluate the pharmacokinetic interactions and safety between single dose\n      of amlodipine 10mg and candesartan 32mg and the combination dose amlodipine 10mg with\n      candesartan 32mg in healthy male volunteers."
        }, 
        "brief_title": "Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male volunteers in the age between 20 and 55 years old(inclusive).\n\n          2. Body weight >= 55kg and Body mass index (BMI) in the range of calculated IBW \u00b120%.\n\n          3. Subjects without a hereditary problems or chronic desease.\n\n          4. Subjects whose clinical laboratory test values are inside the accepted normal range.\n\n          5. Understand the requirements of the study and voluntarily consent to participate in\n             the study.\n\n        Exclusion Criteria:\n\n          1. Subjects with a history of gastrointestinal diseases which might significantly change\n             ADME of medicines.\n\n          2. Systolic blood pressure range \u2265150 mmHg or \u2264 100 mmHg or diastolic blood pressure\n             range \u2265 95 mmHg or \u2264 60 mmHg.\n\n          3. Subject with symptoms of acute disease within 14days prior to study medication\n             dosing.\n\n          4. Subjects with a history of clinically significant allergies of amlodipin or\n             candesartan or CCB or other medicine (ex. aspirin or antibiotics).\n\n          5. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose\n             malabsorption.\n\n          6. Serum creatinine > 1.2mg/dL.\n\n          7. smoking > 10 cigarettes/day.\n\n          8. alcohol > 210g/week.\n\n          9. Positive test results for drug test in urin or subject with history of substance\n             abuse.\n\n         10. Participation in any clinical investigation within 2 months prior to study medication\n             dosing.\n\n         11. Subjects with whole blood donation within 2 months, component blood donation within 1\n             month and blood transfusion within 1 month prior to study medication dosing.\n\n         12. Subjects considered as unsuitable based on medical judgement by investigators."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926652", 
            "org_study_id": "SP-AC-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "candesartan", 
                "amlodipine"
            ], 
            "description": "Part A: Treatment A (candesartan),  Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.\nPart B: Treatment A (Amlodipine),  Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.", 
            "intervention_name": "candesartan cilexetil 32mg, amlodipine 10mg", 
            "intervention_type": "Drug", 
            "other_name": "atacand 32mg, norvasc 10mg"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Candesartan cilexetil", 
                "Candesartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of", 
                    "state": "Chungcheongbul-do", 
                    "zip": "301-721"
                }, 
                "name": "Chungnam national university hospital, clinical trial center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "AUC, Cmax", 
            "safety_issue": "Yes", 
            "time_frame": "7days, 10days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926652"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Cmin, tmax, CL/F", 
            "safety_issue": "Yes", 
            "time_frame": "7days, 10days"
        }, 
        "source": "Shin Poong Pharmaceutical Co. Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shin Poong Pharmaceutical Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}